#VisualAbstract: Peanut oral immunotherapy desensitizes young children with non-anaphylactic peanut allergies
Compared to placebo, children who received peanut oral immunotherapy experienced significantly...
Read MoreMar 11, 2022
Compared to placebo, children who received peanut oral immunotherapy experienced significantly...
Read MoreMar 11, 2022
1. In this randomized controlled trial, combined treatment with varenicline and nicotine patch...
Read MoreMar 9, 2022
Rates of sustained return of spontaneous circulation after non-traumatic out-of-hospital cardiac...
Read MoreMar 9, 2022
1. Melioidosis, caused by Burkholderia pseudomallei, is rarely diagnosed in the US, and patients...
Read MoreMar 9, 2022
1. Provision of an inhaled glucocorticoid and instruction on its use led to a significantly lower...
Read MoreMar 9, 2022
Click to read this study in JAMA Network Open.
Read MoreMar 9, 2022
1. In a diverse population with universal access to health care, tremor and impaired memory...
Read MoreMar 9, 2022
1. In both trials, faricimab was demonstrated to be non-inferior to aflibercept at improving...
Read MoreMar 9, 2022
1. This study demonstrated an inverse dose-response association between cardiorespiratory fitness...
Read MoreMar 9, 2022
1. For patients undergoing only a coronary-artery bypass grafting (CABG) or aortic-valve...
Read MoreMar 9, 2022
Click to read this study in JAMA Network Open.
Read MoreMar 9, 2022
1. In patients with hypertension, intensive blood pressure control to a target of less than 120...
Read MoreMar 9, 2022
1. Faricimab every 8 weeks and faricimab per personalized treatment interval (PTI) were...
Read MoreMar 8, 2022
Association between Treatment for Localized Prostate Cancer and Mental Health Outcomes 1. No...
Read MoreMar 8, 2022
1. Single-dose intramuscular injection of nirsevimab significantly reduced respiratory syncytial...
Read MoreMar 8, 2022
1. Guidelines changes to frequently used outpatient evaluation and management (E/M) billing use...
Read MoreMar 8, 2022
1. The incremental cost-effectiveness ratio of the pertuzumab group was $436,679 per QALY gained....
Read MoreMar 8, 2022
1. The AD26.COV2.S vaccine provided protection against moderate to severe-critical Covid-19. 2....
Read MoreMar 8, 2022
1. Total pathological complete response was not significantly different between trastuzumab and...
Read More